Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Catabasis Pharma (CATB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 46,738
  • Shares Outstanding, K 29,030
  • Annual Sales, $ 500 K
  • Annual Income, $ -27,360 K
  • 36-Month Beta 0.70
  • Price/Sales 93.25
  • Price/Cash Flow N/A
  • Price/Book 3.61

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.56 +1.92%
on 05/25/18
1.81 -12.15%
on 05/09/18
-0.02 (-1.24%)
since 04/25/18
3-Month
1.55 +2.58%
on 04/24/18
2.18 -27.06%
on 03/16/18
-0.15 (-8.62%)
since 02/23/18
52-Week
1.09 +45.87%
on 07/21/17
3.78 -57.94%
on 10/04/17
+0.23 (+16.91%)
since 05/25/17

Most Recent Stories

More News
Keryx (KERX) Loss Narrower than Expected in Q1, Sales Beat

Keryx's (KERX) loss in the first quarter of 2018 was narrower than expected while sales beat estimates. The company remains encouraged by the performance of its lead drug Auryxia.

LGND : 189.25 (-0.09%)
CATB : 1.59 (-1.24%)
KERX : 5.25 (+5.00%)
ENTA : 96.46 (-1.25%)
Intrexon (XON) Q1 Loss Narrower Than Expected, Revenues Miss

Intrexon (XON) incurs narrower-than-expected loss but revenues missed mark in the first quarter of 2018.

LGND : 189.25 (-0.09%)
CATB : 1.59 (-1.24%)
ENTA : 96.46 (-1.25%)
XON : 15.66 (+1.03%)
Endocyte (ECYT) Q1 Loss Narrower Than Expected, Shares Up

Endocyte (ECYT) incurs narrower-than-expected loss in the first quarter of 2018. The company finalized a phase III VISION study design for its pipeline candidate 177Lu-PSMA-617 in the quarter.

LGND : 189.25 (-0.09%)
CATB : 1.59 (-1.24%)
ENTA : 96.46 (-1.25%)
ECYT : 13.33 (-5.19%)
Catalyst (CPRX) Posts In-Line Q1 Loss, Pipeline Progresses

Catalyst reported in-line loss in Q1. The company resubmitted a new drug application for its lead candidate Firdapse and expects FDA to accept the NDA in Q2.

LGND : 189.25 (-0.09%)
CATB : 1.59 (-1.24%)
ENTA : 96.46 (-1.25%)
CPRX : 3.26 (-4.12%)
AMAG Pharma (AMAG) Q1 Loss Wider Than Expected, Lifts View

AMAG incurs wider-than-expected loss in the first quarter of 2018. The company raised 2018 revenue guidance.

PTGX : 6.66 (+0.76%)
LGND : 189.25 (-0.09%)
CATB : 1.59 (-1.24%)
AMAG : 23.70 (+2.60%)
Sarepta (SRPT) Q1 Loss Narrows, Exondys 51 Sales Impress

Sarepta (SRPT) reports narrower-than-expected loss for the first quarter of 2018. However, sales miss estimates.

PTGX : 6.66 (+0.76%)
LGND : 189.25 (-0.09%)
CATB : 1.59 (-1.24%)
SRPT : 91.65 (+1.84%)
Catabasis Pharmaceuticals to Report First Quarter 2018 Financial Results and Recent Corporate Developments on Thursday, May 10

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will report first quarter 2018 financial results before the NASDAQ Global Market open on...

CATB : 1.59 (-1.24%)
Novo Nordisk (NVO) Beats Q1 Earnings Estimates, Sales Miss

Novo Nordisk's (NVO) first-quarter 2018 results beat earnings, but missed on revenue estimates.

PTGX : 6.66 (+0.76%)
LGND : 189.25 (-0.09%)
CATB : 1.59 (-1.24%)
NVO : 47.73 (-0.77%)
Zoetis (ZTS) Beats on Q1 Earnings & Sales, Retains '18 View

Zoetis (ZTS) exceeds both earnings and sales expectations in the first quarter of 2018.

PTGX : 6.66 (+0.76%)
LGND : 189.25 (-0.09%)
CATB : 1.59 (-1.24%)
ZTS : 83.67 (-1.27%)
Shire (SHPG) Q1 Earnings Beat, Rare Disease Franchise Strong

Shire (SHPG) reports better-than-expected first-quarter earnings and records strong growth in immunology franchise and newly launched products.

PTGX : 6.66 (+0.76%)
LGND : 189.25 (-0.09%)
CATB : 1.59 (-1.24%)
SHPG : 165.23 (+0.44%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade CATB with:

Business Summary

Catabasis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of therapeutics for treatment of inflammatory, immunological and metabolic diseases. Its product development pipeline includes CAT-1004, CAT-2000 series including CAT-2054...

See More

Key Turning Points

2nd Resistance Point 1.64
1st Resistance Point 1.61
Last Price 1.59
1st Support Level 1.56
2nd Support Level 1.54

See More

52-Week High 3.78
Fibonacci 61.8% 2.75
Fibonacci 50% 2.43
Fibonacci 38.2% 2.12
Last Price 1.59
52-Week Low 1.09

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar